Noxopharm Limited
ASX:NOX.AX
0.073 (AUD) • At close March 14, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) AUD.
| 2024 Q4 | 2024 Q2 | 2023 Q4 | 2023 Q2 | 2022 Q4 | 2022 Q2 | 2021 Q4 | 2021 Q2 | 2020 Q4 | 2020 Q2 | 2019 Q4 | 2019 Q2 | 2018 Q4 | 2018 Q2 | 2017 Q4 | 2017 Q2 | 2016 Q4 | 2016 Q2 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 1.188 | 1.212 | 2.664 | 3.346 | 3.64 | 1.789 | 4.253 | 1.355 | 4.52 | 3.762 | 0.486 | 3.264 | 0.061 | 0.856 | 0.126 | 0 | 0 | 0 |
| Cost of Revenue
| 1.484 | 0.001 | 0.011 | 0.143 | 0.13 | 0.132 | 0.131 | 0.131 | 0.129 | 0.113 | 0.031 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit
| -0.296 | 1.211 | 2.653 | 3.202 | 3.51 | 1.657 | 4.122 | 1.224 | 4.391 | 3.649 | 0.455 | 3.264 | 0.061 | 0.856 | 0.126 | 0 | 0 | 0 |
| Gross Profit Ratio
| -0.249 | 0.999 | 0.996 | 0.957 | 0.964 | 0.926 | 0.969 | 0.904 | 0.972 | 0.97 | 0.936 | 1 | 1 | 1 | 1 | 0 | 0 | 0 |
| Reseach & Development Expenses
| 1.484 | 1.451 | 4.852 | 5.795 | 4.697 | 3.081 | 5.222 | 3.047 | 3.781 | 3.552 | 3.432 | 2.819 | 1.878 | 2.235 | 0.58 | 0.236 | 0 | 0 |
| General & Administrative Expenses
| 0.52 | 0.521 | 0.577 | 0.9 | 0.742 | 0.922 | 0.838 | 0.756 | 0.54 | 2.505 | 1.237 | 1.496 | 1.012 | 0.777 | 0.545 | 0.41 | 0 | 0 |
| Selling & Marketing Expenses
| 0.058 | 1.498 | 0.192 | 2.127 | 0.104 | 2.399 | 0.129 | 3.526 | 2.172 | 3.575 | 0.02 | 3.146 | 0.053 | 1.853 | 0.107 | 0.027 | 0 | 0 |
| SG&A
| 2.046 | 2.019 | 2.764 | 3.027 | 3.847 | 3.321 | 3.098 | 4.281 | 2.713 | 6.08 | 4.711 | 4.643 | 3.699 | 2.63 | 1.476 | 0.906 | 0 | 0 |
| Other Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -0.091 | -0.091 | 0 | 0 |
| Operating Expenses
| 3.53 | 3.47 | 7.616 | 8.822 | 8.544 | 6.402 | 8.32 | 7.328 | 6.493 | 9.632 | 8.144 | 7.513 | 6.418 | 12.882 | 2.072 | 1.168 | 0 | 0 |
| Operating Income
| -3.826 | -3.471 | -7.627 | -8.965 | -8.674 | -6.534 | -8.451 | -7.459 | -6.622 | -9.745 | -8.175 | -4.228 | -5.56 | -4.025 | -1.943 | -1.159 | 0 | 0 |
| Operating Income Ratio
| -3.22 | -2.864 | -2.863 | -2.68 | -2.383 | -3.653 | -1.987 | -5.504 | -1.465 | -2.59 | -16.809 | -1.295 | -91.116 | -4.704 | -15.385 | 0 | 0 | 0 |
| Total Other Income Expenses Net
| 1.558 | -0.001 | -2.428 | 2.523 | -4.056 | -2.684 | 6.047 | 1.817 | 9.825 | -2.018 | -0.43 | -0.257 | -0.825 | -7.982 | 0.023 | 0.002 | 0 | 0 |
| Income Before Tax
| -2.269 | -3.71 | -12.294 | -8.747 | -13.644 | -10.391 | -2.404 | -7.202 | 3.203 | -11.44 | -8.605 | -4.454 | -6.33 | -11.991 | -1.907 | -1.139 | 0 | 0 |
| Income Before Tax Ratio
| -1.909 | -3.061 | -4.614 | -2.615 | -3.748 | -5.809 | -0.565 | -5.315 | 0.709 | -3.041 | -17.693 | -1.364 | -103.743 | -14.016 | -15.098 | 0 | 0 | 0 |
| Income Tax Expense
| -1.188 | -1.212 | -2.664 | -3.321 | -3.59 | -1.778 | 0.221 | -1.3 | -4.57 | -3.762 | -0.486 | -0.858 | -0.037 | 0 | 0 | 0 | 0 | 0 |
| Net Income
| -1.08 | -2.498 | -9.63 | -5.427 | -10.054 | -8.613 | -2.624 | -6.722 | 6.678 | -6.95 | -6.769 | -3.596 | -6.293 | -11.991 | -1.907 | -1.139 | 0 | 0 |
| Net Income Ratio
| -0.909 | -2.061 | -3.614 | -1.622 | -2.762 | -4.815 | -0.617 | -4.961 | 1.477 | -1.847 | -13.918 | -1.102 | -103.136 | -14.016 | -15.098 | 0 | 0 | 0 |
| EPS
| -0.004 | -0.009 | -0.033 | -0.019 | -0.034 | -0.03 | -0.009 | -0.031 | 0.031 | -0.05 | -0.049 | -0.03 | -0.055 | -0.12 | -0.022 | -0.016 | 0 | 0 |
| EPS Diluted
| -0.004 | -0.009 | -0.033 | -0.019 | -0.034 | -0.03 | -0.009 | -0.031 | 0.031 | -0.05 | -0.049 | -0.03 | -0.055 | -0.12 | -0.022 | -0.016 | 0 | 0 |
| EBITDA
| -2.342 | -3.683 | -12.25 | -8.596 | -13.449 | -10.247 | -8.359 | -6.218 | -2.049 | -9.647 | -8.234 | -4.197 | -5.516 | -4.009 | -1.942 | -1.122 | 0 | 0 |
| EBITDA Ratio
| -1.971 | -2.863 | -2.858 | -2.637 | -2.347 | -3.579 | -1.956 | -5.408 | -1.437 | -2.56 | -16.745 | -1.286 | -90.406 | -4.686 | -15.374 | 0 | 0 | 0 |